Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas

Matthias P A Ebert, Fabian Model, Suzanne Mooney, Kari Hale, Joe Lograsso, Lori Tonnes-Priddy, Juliane Hoffmann, Antal Csepregi, Christoph Röcken, B. Molnár, Hans Ulrich Schulz, Peter Malfertheiner, Catherine Lofton-Day

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background & Aims: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy. Methods: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified. Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma. ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer. Results: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P <.0001). In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P <.001). ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P <.0001). Using a cutoff of 41.4 pg/mL, sensitivity and specificity were 83.3% and 70%, respectively. Conclusions: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract. ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.

Original languageEnglish
Pages (from-to)1418-1430
Number of pages13
JournalGastroenterology
Volume131
Issue number5
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Homeobox Genes
Methylation
Adenocarcinoma
Adenoma
Colonic Neoplasms
Colorectal Neoplasms
Colon
Liver Neoplasms
Neoplasms
Serum
Gastrointestinal Neoplasms
Cholangiocarcinoma
Esophageal Neoplasms
Bile Ducts
Genetic Markers
Epigenomics
Stomach Neoplasms
Gastrointestinal Tract
Stomach
Mucous Membrane

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ebert, M. P. A., Model, F., Mooney, S., Hale, K., Lograsso, J., Tonnes-Priddy, L., ... Lofton-Day, C. (2006). Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas. Gastroenterology, 131(5), 1418-1430. https://doi.org/10.1053/j.gastro.2006.08.034

Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas. / Ebert, Matthias P A; Model, Fabian; Mooney, Suzanne; Hale, Kari; Lograsso, Joe; Tonnes-Priddy, Lori; Hoffmann, Juliane; Csepregi, Antal; Röcken, Christoph; Molnár, B.; Schulz, Hans Ulrich; Malfertheiner, Peter; Lofton-Day, Catherine.

In: Gastroenterology, Vol. 131, No. 5, 11.2006, p. 1418-1430.

Research output: Contribution to journalArticle

Ebert, MPA, Model, F, Mooney, S, Hale, K, Lograsso, J, Tonnes-Priddy, L, Hoffmann, J, Csepregi, A, Röcken, C, Molnár, B, Schulz, HU, Malfertheiner, P & Lofton-Day, C 2006, 'Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas', Gastroenterology, vol. 131, no. 5, pp. 1418-1430. https://doi.org/10.1053/j.gastro.2006.08.034
Ebert MPA, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L et al. Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas. Gastroenterology. 2006 Nov;131(5):1418-1430. https://doi.org/10.1053/j.gastro.2006.08.034
Ebert, Matthias P A ; Model, Fabian ; Mooney, Suzanne ; Hale, Kari ; Lograsso, Joe ; Tonnes-Priddy, Lori ; Hoffmann, Juliane ; Csepregi, Antal ; Röcken, Christoph ; Molnár, B. ; Schulz, Hans Ulrich ; Malfertheiner, Peter ; Lofton-Day, Catherine. / Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas. In: Gastroenterology. 2006 ; Vol. 131, No. 5. pp. 1418-1430.
@article{026a8e6e9b79441b8700765edee2fbcf,
title = "Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas",
abstract = "Background & Aims: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy. Methods: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified. Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma. ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer. Results: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P <.0001). In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P <.001). ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P <.0001). Using a cutoff of 41.4 pg/mL, sensitivity and specificity were 83.3{\%} and 70{\%}, respectively. Conclusions: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract. ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.",
author = "Ebert, {Matthias P A} and Fabian Model and Suzanne Mooney and Kari Hale and Joe Lograsso and Lori Tonnes-Priddy and Juliane Hoffmann and Antal Csepregi and Christoph R{\"o}cken and B. Moln{\'a}r and Schulz, {Hans Ulrich} and Peter Malfertheiner and Catherine Lofton-Day",
year = "2006",
month = "11",
doi = "10.1053/j.gastro.2006.08.034",
language = "English",
volume = "131",
pages = "1418--1430",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Aristaless-like Homeobox-4 Gene Methylation Is a Potential Marker for Colorectal Adenocarcinomas

AU - Ebert, Matthias P A

AU - Model, Fabian

AU - Mooney, Suzanne

AU - Hale, Kari

AU - Lograsso, Joe

AU - Tonnes-Priddy, Lori

AU - Hoffmann, Juliane

AU - Csepregi, Antal

AU - Röcken, Christoph

AU - Molnár, B.

AU - Schulz, Hans Ulrich

AU - Malfertheiner, Peter

AU - Lofton-Day, Catherine

PY - 2006/11

Y1 - 2006/11

N2 - Background & Aims: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy. Methods: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified. Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma. ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer. Results: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P <.0001). In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P <.001). ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P <.0001). Using a cutoff of 41.4 pg/mL, sensitivity and specificity were 83.3% and 70%, respectively. Conclusions: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract. ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.

AB - Background & Aims: The identification of novel genetic and epigenetic markers indicative of changes in the pathogenesis of colon cancer, along with easier-to-use, more sensitive assay methods, may improve the detection, treatment, and overall prognosis of this malignancy. Methods: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified. Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma. ALX4 methylation was also analyzed in the serum of 30 patients with colon cancer. Results: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P <.0001). In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P <.001). ALX4 gene methylation was also more frequently found in sera of patients with colon cancer compared with noncancer controls (P <.0001). Using a cutoff of 41.4 pg/mL, sensitivity and specificity were 83.3% and 70%, respectively. Conclusions: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract. ALX4 gene methylation in sera of patients with cancer may thus serve as a methylation-specific test for colon and other gastrointestinal cancers.

UR - http://www.scopus.com/inward/record.url?scp=33750701826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750701826&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2006.08.034

DO - 10.1053/j.gastro.2006.08.034

M3 - Article

C2 - 17101318

AN - SCOPUS:33750701826

VL - 131

SP - 1418

EP - 1430

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -